Y.D. More Investments Ltd Trims Stock Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Y.D. More Investments Ltd trimmed its position in Cellebrite DI Ltd. (NASDAQ:CLBT) by 10.9% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 301,734 shares of the company’s stock after selling 37,016 shares during the quarter. Y.D. More Investments Ltd’s holdings in Cellebrite DI were worth $6,647,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in CLBT. Quarry LP acquired a new stake in shares of Cellebrite DI in the 3rd quarter worth $27,000. Advisors Asset Management Inc. raised its stake in Cellebrite DI by 130.5% in the 3rd quarter. Advisors Asset Management Inc. now owns 3,077 shares of the company’s stock worth $52,000 after acquiring an additional 1,742 shares during the last quarter. Pathway Financial Advisers LLC grew its stake in Cellebrite DI by 1,583.8% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,378 shares of the company’s stock valued at $74,000 after purchasing an additional 4,118 shares during the last quarter. R Squared Ltd acquired a new position in shares of Cellebrite DI in the fourth quarter valued at about $100,000. Finally, Venturi Wealth Management LLC lifted its holdings in shares of Cellebrite DI by 28.6% during the third quarter. Venturi Wealth Management LLC now owns 9,000 shares of the company’s stock worth $152,000 after purchasing an additional 2,000 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.

Cellebrite DI Stock Up 3.2 %

NASDAQ:CLBT opened at $25.46 on Wednesday. The stock has a 50 day moving average price of $21.87 and a 200 day moving average price of $18.54. Cellebrite DI Ltd. has a one year low of $8.91 and a one year high of $25.95.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.09 by $0.05. Cellebrite DI had a positive return on equity of 122.59% and a negative net margin of 82.28%. The business had revenue of $106.90 million for the quarter, compared to analyst estimates of $102.06 million. During the same quarter in the previous year, the firm earned $0.09 EPS. The company’s quarterly revenue was up 27.0% compared to the same quarter last year. As a group, equities analysts forecast that Cellebrite DI Ltd. will post 0.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on the stock. Craig Hallum lifted their price objective on shares of Cellebrite DI from $23.00 to $24.00 and gave the company a “buy” rating in a research note on Thursday, November 7th. Needham & Company LLC boosted their price objective on Cellebrite DI from $21.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. raised their target price on Cellebrite DI from $22.00 to $24.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $21.57.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.